### In vitro / physico-chemical Data

A literature search was performed to collect available information on physiochemical properties of R- and S-verapamil and R- and S-norverapamil. The obtained information from literature is summarized in the tables below. 

#### R-verapamil

| **Parameter**   | **Unit** | **Value**       | Source                                                       | **Description**                                 |
| :-------------- | -------- | --------------- | ------------------------------------------------------------ | ----------------------------------------------- |
| MW              | g/mol    | 454.611     | [Wishart 2006](#5-references)                                    | Molecular weight                                |
| pK<sub>a</sub> (base)  | -  | 8.75          | [Hasegawa 1984](#5-references)              | Acid dissociation constant                      |
| Solubility (pH 6.54) | g/L     | 46.0 | [Vogelpoel 2004](#5-references)    | Water solubility                               |
| logP            |  | 3.79                       | [Hansch  1995](#5-references) | Partition coefficient between octanol and water |
| fu              |  %       | 5.1 | [**Sanaee 2011**](#5-references) | Fraction unbound in plasma                      |
| CYP3A4 Km -> Norvera            | µmol/L | 19.59 | [Wang 2013](#5-references) | CYP3A4 Michaelis-Menten constant for norverapamil formation    |
| CYP3A4 Km -> D617		  | µmol/L | 35.34 | [Wang 2013](#5-references) | CYP3A4 Michaelis-Menten constant for D617 formation    |
| P-gp Km		  | µmol/L | 1.01 | [Shirasaka 2008](#5-references) | Pgp Michaelis-Menten constant    |
| CYP3A4 MBI KI		  | µmol/L | 27.63 | [Wang 2013](#5-references) | Conc. for half-maximal inactivation    |
| CYP3A4 MBI kinact		  | 1/min | 0.038 | [Wang 2013](#5-references) | Maximum inactivation rate    |
| Pgp non-competitive Ki		  | µmol/L | 0.31 | Döppenschmitt 1999 (#5-references) | Conc. for half-maximal inactivation    |

#### S-verapamil

| **Parameter**   | **Unit** | **Value**       | Source                                                       | **Description**                                 |
| :-------------- | -------- | --------------- | ------------------------------------------------------------ | ----------------------------------------------- |
| MW              | g/mol    | 454.611     |[Wishart 2006](#5-references)                                    | Molecular weight                                |
| pK<sub>a</sub> (base)  | -  | 8.75          | [Hasegawa 1984](#5-references)            | Acid dissociation constant                      |
| Solubility (pH 6.54) | g/L     | 46.0 | [Vogelpoel 2004](#5-references) | Water solubility                               |
| logP            |  | 3.79                       | [Hansch  1995](#5-references) | Partition coefficient between octanol and water |
| fu              |  %       | 11 | [**Sanaee 2011**](#5-references) | Fraction unbound in plasma                      |
| CYP3A4 Km -> Norvera            | µmol/L | 9.72 | [Wang 2013](#5-references) | CYP3A4 Michaelis-Menten constant for norverapamil formation    |
| CYP3A4 Km -> D617		  | µmol/L | 23.64 | [Wang 2013](#5-references) | CYP3A4 Michaelis-Menten constant for D617 formation    |
| P-gp Km		  | µmol/L | 1.01 | [Shirasaka 2008](#5-references) | Pgp Michaelis-Menten constant    |
| CYP3A4 MBI KI		  | µmol/L | 3.85 | [Wang 2013](#5-references) | Conc. for half-maximal inactivation    |
| CYP3A4 MBI kinact		  | 1/min | 0.034 | [Wang 2013](#5-references) | Maximum inactivation rate    |
| Pgp non-competitive Ki		  | µmol/L | 0.31 | Döppenschmitt 1999 (#5-references) | Conc. for half-maximal inactivation    |

#### R-norverapamil

| **Parameter**   | **Unit** | **Value**       | Source                                                       | **Description**                                 |
| :-------------- | -------- | --------------- | ------------------------------------------------------------ | ----------------------------------------------- |
| MW              | g/mol    | 440.584     | [Wishart 2006](#5-references)                                    | Molecular weight                                |
| pK<sub>a</sub> (base)  | -  | 8.6 - 8.9          | [Sigma-Aldrich 2013](#5-references)             | Acid dissociation constant                      |
| fu              |  %       | 5.1 | assumed (from parent) | Fraction unbound in plasma                      |
| CYP3A4 Km -> D620            | µmol/L | 144 | [Tracy 1999](#5-references) | CYP3A4 Michaelis-Menten constant for norverapamil degradation |
| P-gp Km		  | µmol/L | 1.01 | assumed (from parent) | Pgp Michaelis-Menten constant    |
| CYP3A4 MBI KI		  | µmol/L | 6.1 | [Wang 2013](#5-references) | Conc. for half-maximal inactivation    |
| CYP3A4 MBI kinact		  | 1/min | 0.048 | [Wang 2013](#5-references) | Maximum inactivation rate    |
| Pgp non-competitive Ki		  | µmol/L | 0.30 | [Pauli-Magnus 2000](#5-references) | Conc. for half-maximal inactivation    |

#### S-norverapamil

| **Parameter**   | **Unit** | **Value**       | Source                                                       | **Description**                                 |
| :-------------- | -------- | --------------- | ------------------------------------------------------------ | ----------------------------------------------- |
| MW              | g/mol    | 440.584     | [Wishart 2006](#5-references)                                    | Molecular weight                                |
| pK<sub>a</sub> (base)  | -  | 8.6 - 8.9          | [Sigma-Aldrich 2013](#5-references)            | Acid dissociation constant                      |
| fu              |  %       | 11 | assumed (from parent) | Fraction unbound in plasma                      |
| CYP3A4 Km -> D620            | µmol/L | 36 | [Tracy 1999](#5-references) | CYP3A4 Michaelis-Menten constant for norverapamil degradation |
| P-gp Km		  | µmol/L | 1.01 | assumed (from parent) | Pgp Michaelis-Menten constant    |
| CYP3A4 MBI KI		  | µmol/L | 2.90 | [Wang 2013](#5-references) | Conc. for half-maximal inactivation    |
| CYP3A4 MBI kinact		  | 1/min | 0.080 | [Wang 2013](#5-references) | Maximum inactivation rate    |
| Pgp non-competitive Ki		  | µmol/L | 0.30 | [Pauli-Magnus 2000](#5-references) | Conc. for half-maximal inactivation    |




### Clinical Data

A literature search was performed to collect available clinical data on verapamil in healthy adults.

#### Model Building and parameterizing of CYP3A4 interaction

The following studies were used for model building and parameterization of CYP3A4 interaction:
If not stated otherwise, the drug was given as a 1:1 racemat of S- and R-verapamil.


| Publication                      | Arm / Treatment / Information used for model building        |
| :------------------------------- | :----------------------------------------------------------- |
| [Eichelbaum 1984](#5-references) | Healthy subjects receiving single intravenous doses of 5, 25 and 50 mg of R-verapamil and 5, 7.5 and 10 mg of S-verapamil |
| [Streit 2005](#5-references) | Healthy subjects receiving single intravenous doses of 5 mg |
| [Barbarash 1988](#5-references)  | Healthy subjects receiving single intravenous doses of 10 mg |
| [Abernethy 1993](#5-references) | Healthy subjects receiving single intravenous doses of 20 mg |
| [Maeda 2011](#5-references) | Healthy subjects receiving single oral doses of 0.1, 3 and 16 mg |
| [Blume 1989](#5-references) | Healthy subjects receiving single oral doses of 80 mg |
| [Ratiopharm 1988](#5-references) | Healthy subjects receiving single oral doses of 80 mg |
| [Johnson 2001](#5-references)   | Healthy subjects receiving multiple oral doses of 80 mg TID. | 
| [Härtter 2012](#5-references) | Healthy subjects receiving single oral doses of 120 mg and multiple oral doses of 120 mg BID |
| [Hla 1987](#5-references)       | Healthy subjects receiving multiple oral doses of 120 mg BID |

#### Model verification 

The following studies were used for model verification:

| Publication                      | Arm / Treatment / Information used for model building        |
| :------------------------------- | :----------------------------------------------------------- |
| [Mooy 1985](#5-references) |  Healthy subjects receiving single intravenous doses of 3 mg and single oral doses of 80 mg |
| [Johnston 1981](#5-references)   | Healthy subjects receiving single intravenous doses of 0.1 mg/kg and single oral doses of 120 mg |
| [Abernethy 1985](#5-references) | Healthy subjects receiving single intravenous doses of 10 mg and single oral doses of 120 mg |
| [Barbarash 1988](#5-references)  | Healthy subjects receiving single oral doses of 120 mg |
| [Wing 1985](#5-references) | Healthy subjects receiving single intravenous doses 10mg and single oral doses of 80 mg |
| [McAllister 1982](#5-references) | Healthy subjects receiving single intravenous doses of 10 mg |
| [Smith 1984](#5-references) | Healthy subjects receiving single intravenous doses of 10 mg and single oral doses of 120 mg |
| [Freedman 1981](#5-references) | Healthy subjects receiving single intravenous doses of 13.1 mg |
| [Vogelsang 1984](#5-references) | Healthy subjects receiving single oral doses of 250mg R-verapamil |
| [Blume 1983](#5-references) | Healthy subjects receiving single oral doses of 40 mg |
| [Blume 1990](#5-references) | Healthy subjects receiving single oral doses of 40 mg |
| [John 1992](#5-references) | Healthy subjects receiving single oral doses of 40 mg |
| [Sawicki 2002](#5-references) | Healthy subjects receiving single oral doses of 40 mg |
| [Choi 2008](#5-references) | Healthy subjects receiving single oral doses of 60 mg |
| [Wing 1985](#5-references) | Healthy subjects receiving single oral doses of 80 mg |
| [Maeda 2011](#5-references) | Healthy subjects receiving single oral doses of 80 mg |
| [Ratiopharm 1989](#5-references) | Healthy subjects receiving single oral doses of 80 mg |
| [Boehringer 2018](#5-references) | Healthy subjects receiving single oral doses of 120 mg |
| [Blume 1987](#5-references) | Healthy subjects receiving single oral doses of 120 mg |
| [Johnston 1981](#5-references) | Healthy subjects receiving single oral doses of 120 mg |
| [Mikus 1990](#5-references) | Healthy subjects receiving single oral doses of 160 mg |
| [van Haarst 2009](#5-references) | Healthy subjects receiving multiple oral doses of 180 mg BID |
| [Blume 1994](#5-references) | Healthy subjects receiving single oral doses of 240 mg QD |
| [Joergenson 1988](#5-references) | Healthy subjects receiving multiple oral doses of 120 mg BID |
| [Shand 1981](#5-references)     | Healthy subjects receiving multiple oral doses of 120 mg TID |
| [Karim 1995](#5-references)     | Healthy subjects receiving single oral doses of 240 mg |
